ClinicalTrials.gg
CompletedNCT00558337Updated Jan 14, 2009

Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Study of L-Dopa/Carbidopa To Treat Parkinson's Disease

A Phase 2 interventional study of levodopa-carbidopa in Parkinson's Disease, sponsored by Osmotica Pharmaceutical US LLC. Completed at 9 sites in Argentina. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2009-01-14.

Sponsored by Osmotica Pharmaceutical US LLC · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
30 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies testing levodopa in Parkinson Disease — 3 open to participants now, 3 under way, none of them phase 3. Levodopa · Parkinson Disease.

Enrollment
22nd of 50
78 · median 56
Started
2007
with 2 others
Phase 2
9 of 51
none open now
Registered
18th of 51
by date

Among the 51 studies testing levodopa in Parkinson Disease, this one is the 22nd largest by enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2007, is one of 9 in phase 2, and was the 18th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

3 of the 51 studies testing levodopa in Parkinson Disease are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About levodopa

Levodopa: first FDA approval 1970 (LARODOPA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing levodopa in Parkinson Disease, or all of them as a file.
02

Study summary

Determine if a novel levodopa/carbidopa formulation results in a better clinical response on Parkinson's Disease patients compared to the reference formulation of levodopa/carbidopa in terms of motor complications, onset of action and response duration.

Read the detailed description

Primary objective is to demonstrate a better clinical response profile of novel levodopa/carbidopa formulation vs. the reference formulation of levodopa/carbidopa in patients with Parkinson's Disease as judged by motor performance and to describe pharmacokinetic profile for the novel formulation compared to the reference.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

Keywords

  • Treatment of Parkinson's Disease
04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnostic of Parkinson's Disease, with a Hoehn and Yahr Staging within 2-4, and L-Dopa therapy complications
  • at least 2years of L-Dopa therapy
  • Patients with the ability to differentiate between "ON" and "OFF" periods
  • Patients who have been receiving stable doses of L-Dopa between 600 and 1600 mg/day, for at least 2 months prior to the screening visit using a dosing regimen not higher that 5 times a day, and not expected in the investigator's opinion to need any dose modifications over the duration of the study
  • Patients presenting a score of at least 2 in the UPDRS IVa, item 32 and/or a score of at least 2 in the UPDRS IVb, item 39, at screening and randomization visits based on clinical records for the first visit and daily diary cards at randomization time.
  • Willing and able to understand and sign form

Exclusion criteria

Exclusion Criteria:

  • Patients with a diagnosis of any known secondary Parkinsonian syndrome, (vascular, toxin or drug-induced, metabolic or infectious, etc) or other neurodegenerative disorder with parkinsonism (Progressive Supranuclear Palsy, Corticobasal Degeneration, Multiple System Atrophy, etc).
  • Patients receiving other concomitant anti-Parkinsonian pharmacological therapies affecting L-dopa or dopamine metabolisom (COMT inhibitors or MAO inhibitors)
  • Subjects who have undergone prior functional neurosurgical treatment for PD (ablation or Deep Brain Stimulation).
  • Patient with a L-dopa dosage regimen greater than 5 times a day which is not able to be adapted to a q.i.d. regimen.
  • Patients having received L-dopa / Decarboxylase inhibitors therapy for less than 2 years.
  • Patients needing nightly doses of L-dopa / Decarboxylase inhibitors apart from the four daily doses.
  • Any medical condition or past medical history that, in the investigator's judgment, would increase the risk of exposure to L-dopa / Carbidopa or interfere with the evaluation of the study objectives.
  • Patients with unstable or known medical illness; such as cardiac, pulmonary, kidney, hepatic and/or gastrointestinal disease that would, in the investigator's judgment, interfere with the safe course of the study.
  • Cognitive impaired patients, as determined by a score of lesser than 26 on the Mini-Mental Score Status Examination. ( \< 26).
  • Alcohol or illegal drugs abuse.
  • Pregnant or lactating patients.
  • to any of the drugs, based on known allergies to drugs of the same class.
  • Patients having taken any research drugs over the last 30 days prior to the beginning of the study.
  • Blood donation, or blood products, or participation to a clinical trial with serial blood withdrawals, within twelve weeks prior to the start of the trial, or intention to donate blood or blood products within three months following the study completion.
  • Patients who have received some of the following medications with an anticipation of no more than 7 treatment-drug elimination half-lives of entry time: Dopamine D2 receptor antagonists , isoniazid, anti-epileptic drugs, IMAO A or B, pyridoxine, ferrous salts or methyldopa.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
78 participants (actual)

Study arms

  • Active comparator
    A

    Drug: levodopa-carbidopa

  • Active comparator
    B

    Drug: levodopa-carbidopa

Interventions

  • Druglevodopa-carbidopa

    Drug pages: Levodopa · Carbidopa

    novel levodopa/carbidopa formulation or a reference levodopa/carbidopa formulation

06

What researchers measure

Primary outcomes

  1. Evidence of a novel levodopa/carbidopa formulation providing a better clinical profile than reference levodopa/carbidopa formulation using Unified Parkinson's Disease Rating Scale (UPDRS III) and patient's diary cards

    Time frame: every half hour for the first 8 hours after dosing

Secondary outcomes

  1. Other measurements to be used for demonstrating clinical profile is UPDRS II and IV, Clinical Global Impression Scale (CGI)/Patient's Global Improvement Scale (PGI), and the Abnormal Involuntary Movement Scale (AIMS)

    Time frame: over the course of the study

07

Study locations

9 sites
  • Fundacion Alfredo Thomson
    Buenos Aires, Argentina
  • Hospital Posadas
    Buenos Aires, Argentina
  • Hospital Ramos Mejía
    Buenos Aires, Argentina
  • Hospital Sirio Libanés
    Buenos Aires, Argentina
  • Instituto Frenopático
    Buenos Aires, Argentina
  • nstituto INEBA
    Buenos Aires, Argentina
  • Policlínica Bancaria
    Buenos Aires, Argentina
  • Fundación Rosarina de Neuro-Rehabilitación
    Rosario, Argentina
  • Hospital San Bernardo
    Salta, Argentina
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2007
First posted
Nov 14, 2007
Start
Nov 2007
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Last update
Jan 14, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00558337
Lead sponsor
Osmotica Pharmaceutical US LLC
First posted
Nov 14, 2007
Start date
Nov 2007
Primary completion
Dec 2008
Completion
Dec 2008
Last update
Jan 14, 2009

Study contacts

Gustavo Fischbein, M.D.
study director · Osmotica Pharmaceutical Argentina S.A.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Levodopa · Carbidopa

Start the discussion